课题基金 / 基金详情

In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality

In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality
通过核医学方式进行基因定位和表达的体内诊断
批准号:
13670965
负责人:
NAKAMURA Kayoko
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003

项目摘要

项目成果

NAKAMURA Kayoko的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是发展核医学技术,用于基因定位和表达的非侵入性诊断。基因在这里指的是为基因治疗而注射的基因或因疾病而过度表达的基因。利用人表皮样瘤细胞系KB-31及其多药耐药细胞系KB-G2进行了实验研究。通过与马萨诸塞州医学院教授唐纳德·J·哈纳托维奇博士的合作,获得了以下结果:1.合成并修饰了与mdr-1相关的反义(AS)和正义(S)寡核苷酸(均为硫代化),然后通过MAG_3或HYNIC配体标记~(99m)Tc。结果1.获得了比活性较高的TC-99m-AS和TC-99m-S,且不失其反义结合活性。用AS或S处理KB-31或KB-G2细胞,再与99m-MIBI孵育,评价P-糖蛋白(mdr-1表达)功能。AS处理的KB-G2细胞的P-gp功能受到抑制,而S.KB-31处理的KB-G2细胞未表现出明显的P-gp功能。TC-99m-As在KB-G2细胞中积累,而在KB-31细胞中未被摄取,而在KB-G2和KB-31细胞中均未被摄取。这些结果表明,As是通过反义作用积累到细胞内的。分别给荷KB-G2或KB-31的小鼠注射99m-As或99m-S。KB-G2肿瘤对99m-AS的摄取明显高于KB-31肿瘤。KB-G2肿瘤对TC-99m-AS的摄取显著高于TC-99m-S。这些结果表明,通过反义勃起可以将99m-AS特异性地定位到MDR-1肿瘤中,为反义显像的成功奠定了基础。
英文摘要
The aim of this investigation is to develop nuclear medicine techniques for non-invasive diagnosis of gene localization and expression. Gene here means the one injected for gene therapy or the other over-expressed due to the disease. Using human epidermoid tumor cell line ; KB-31 and its mdr-1 transfected cell line ; KB-G2 carried out the study. By co-working with Dr. Donald J Hnatowich, Professor of Massachusetts Medical School, the following results were obtained;1. Antisense (AS) and sense (S) oligonucleotides related to mdr-1 were synthesized and modified (all phosphothiolated) and then, labeled with Tc-99m via MAG3 or HYNIC ligands. Tc-99m-AS and Tc-99m-S were obtained with high specific activity without loosing their antisense-binding affinity.2. KB-31 or KB-G2 were treated with AS or S, followed by incubation with Tc-99m-MIBI, which is to evaluate P-glycoprotein (mdr-1 expression) function. The KB-G2 treated with AS suppressed the P-gp function, while it was not shown in KB-G2 treated by S. KB-31 did not show any influence by treating with AS or S. These results indicated the antisense effect of AS oligonucleiotied we used.3. Tc-99m-AS was accumulated in KB-G2 but not in KB-31, while Tc-99m-S was not taken up either in KB-G2 or KB-31. These results indicated that AS was accumulated into the cell by antisense effect.4. Tc-99m-AS or Tc-99m-S was injected into the mice bearing KB-G2 or KB-31. The uptake of Tc-99m-AS in the KB-G2 tumor was significantly higher than that in the KB-31 tumors. Tc-99m-AS uptake in KB-G2 tumor was significantly higher than Tc-99m-S. These results indicated that Tc-99m-AS was localized into the mdr-1-tumors specifically by antisense erect.All these results would lead the success for the antisense imaging.
期刊论文(80)
专著(0)
科研奖励(0)
会议论文
中村 佳代子: "遺伝子と臨床核医学(9):クローン、クローニング、cDNA"臨床核医学. 35(2). 27-29 (2002)
Kayoko Nakamura:“基因与临床核医学 (9):克隆、克隆、cDNA”临床核医学 35(2) (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kayoko Nakamura: "Can Tc-99m-MIBI assess MDR-modulators?"European Journal of Nuclear Medicine. 29(S1). S381 (2002)
Kayoko Nakamura:“Tc-99m-MIBI 可以评估 MDR 调节剂吗?”欧洲核医学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
中村 佳代子<分担>: "Sentinel Node Navigation-癌治療への新しい展開-センチネルリンパ節の核医学的検出に用いる放射性医薬品"金原出版株式会社. 296 (2002)
Kayoko Nakamura <贡献者>:“前哨淋巴结导航 - 癌症治疗的新进展 - 用于前哨淋巴结核医学检测的放射性药物” Kanehara Publishing Co., Ltd. 296 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
中村 佳代子: "医療現場は科学の実地教育現場-放射線医学教育を通して科学的な考え方を育てる-"広領域教育. 52. 53-57 (2003)
Kayoko Nakamura:“医疗场所是实用的科学教育场所 - 通过放射学教育发展科学思维”广泛学科教育。52. 53-57 (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 79 条
    Optical and Nuclear Imaging of Tumor-related genes
    • 批准号:
      19591434
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      NAKAMURA Kayoko
    • 依托单位:
    Gene Imaging for Studying Pharmacokinetics of Gene in Vivo at the Real Time
    • 批准号:
      16591225
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2004
    • 负责人:
      NAKAMURA Kayoko
    • 依托单位:
    Development of Nuclear Medicine Modality for Selecting Cancer Therapy and for Predicting Therapeutic Efficacy from Molecular Biological Points of View
    • 批准号:
      11670912
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      1999
    • 负责人:
      NAKAMURA Kayoko
    • 依托单位:
    Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine
    • 批准号:
      09670954
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.98万
    • 财政年份:
      1997
    • 负责人:
      NAKAMURA Kayoko
    • 依托单位:
    国内基金
    海外基金
    基于中国散裂中子源伴生质子束的医用同位素Tc-99m产生研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      15.0万元
    • 批准年份:
      2024
    • 负责人:
      敬罕涛
    • 依托单位:
    表面修饰碳纳米管对Tc-99m同位素分离纯化性能的影响研究
    用于肿瘤诊断和个性化治疗的Tc-99m/Re-188标记的σ2受体放射性药物研究
    • 批准号:
      21471019
    • 项目类别:
      面上项目
    • 资助金额:
      80.0万元
    • 批准年份:
      2014
    • 负责人:
      贾红梅
    • 依托单位:
    Tc-99m标记的σ2受体肿瘤分子探针的研究
    • 批准号:
      21071023
    • 项目类别:
      面上项目
    • 资助金额:
      35.0万元
    • 批准年份:
      2010
    • 负责人:
      贾红梅
    • 依托单位: